Thursday, 15 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 27, 2026

Anthropic eyes an October IPO, which could raise over $60B

View original at finance.yahoo.com
Anthropic eyes an October IPO, which could raise over $60B Yahoo Finance Technology Editor Dan Howley joins Josh Lipton to break down reports that Anthropic (ANTH.PVT) could go public as soon as October, as it looks to get ahead of OpenAI (OPAI.PVT) in the intensifying AI race…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Anthropic wants to get ahead of OpenAI in the IPO race

    60% confidence

  • Outside of Google and Microsoft, Anthropic IPO is one of the biggest ways to invest in AI model companies

    60% confidence

  • OpenAI has been paring down offerings to refocus

    60% confidence

  • Revenue versus spending is better for Anthropic compared to OpenAI

    60% confidence

  • Anthropic could go public as soon as October and raise over $60 billion

    60% confidence

  • Anthropic is positioning itself as the more refined option for AI investors

    60% confidence

  • Investor risks for Anthropic include spending, competition, and regulation

    60% confidence

Data points we hold from this source

Anthropic · potential ipo valuation60 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
Anthropic eyes an October IPO, which could raise over $60B — Source | Via News | ViaNews EU